Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/01/2012 | 02:13pm CEST

Endo Pharmaceuticals Holdings Inc.'s (>> Endo Pharmaceuticals Holdings Inc) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition.

Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late.

First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply.

Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant.

Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million.

Gross margin fell to 47.2% from 58.7%.

Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%.

Overall branded drug sales were down 3% while generics sales increased 8%.

Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stocks mentioned in the article : Endo Pharmaceuticals Holdings Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ENDO HEALTH SOLUTIONS INC
08/08 ENDO INTERNATIONAL PLC : Investor Network: Endo International Plc to Host Earnin..
08/02 ENDO INTERNATIONAL PLC : Pomerantz Law Firm Investigates Claims On Behalf of Inv..
07/25 ENDO INTERNATIONAL PLC : Featured Company News - Endo's Restructuring of its Man..
07/22 ENDO INTERNATIONAL PLC : Pomerantz Law Firm Investigates Claims On Behalf of Inv..
07/12 ENDO INTERNATIONAL PLC : Pomerantz Law Firm Investigates Claims On Behalf of Inv..
07/08 ENDO INTERNATIONAL PLC : Lundin Law PC Announces an Investigation of Endo Intern..
06/30 ENDO INTERNATIONAL PLC : Pomerantz Law Firm Investigates Claims On Behalf of Inv..
06/26 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Announces Investigat..
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJR. JOHNSON : Missouri Files Its Own Suit Against Opioid-Painkiller Producers -- ..
More news
Financials ($)
Sales 2017 3 465 M
EBIT 2017 1 402 M
Net income 2017 46,1 M
Debt 2017 5 409 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 6,89
EV / Sales 2017 2,12x
EV / Sales 2018 2,91x
Capitalization 1 947 M
Technical analysis trends ENDO HEALTH SOLUTIONS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 20
Average target price 12,6 $
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Paul V. Campanelli President, Chief Executive Officer & Director
Roger H. Kimmel Chairman
Terrance J. Coughlin Chief Operating Officer & Executive Vice President
Blaise Coleman Chief Financial Officer & Executive Vice President
Robert J. Cobuzzi SVP-Operations, Research & Development Strategy